In August 2014, OptiBiotix went public via the reverse takeover of AIM listed investment company Ducat Ventures plc. This transaction brought to market a company active in one of the most progressive areas of biotechnological research, the human microbiome, the collective genome of the microbes in the body, a metabolically active, rapidly renewable ecosystem which is being increasingly linked to host immunity, metabolism and physiology. Advances in our understanding of this enormous gene pool ....